The landscape of non-cystic fibrosis bronchiectasis (NCFB) treatment is undergoing a significant transformation with the emergence of Brinsupri (brensocatib), a groundbreaking therapy developed by Insmed. As the first-to-market dipeptidyl peptidase 1 (DPP1) inhibitor, Brinsupri is strategically positioned to become the new standard of care for patients suffering from this chronic and debilitating respiratory condition. Insmed’s significant presence at the 2026 American Thoracic Society (ATS) International Conference underscored the company’s commitment to advancing NCFB care and solidifying Brinsupri’s clinical profile. The conference served as a pivotal platform for disseminating new data, fostering disease awareness, and engaging with the medical community on the therapeutic potential of this first-in-class DPP1 inhibitor.
Insmed’s Multifaceted Approach at ATS 2026
Insmed’s participation at ATS 2026 was characterized by a comprehensive and coordinated strategy aimed at highlighting Brinsupri’s efficacy and addressing the unmet needs in NCFB. The company’s presence extended beyond mere exhibition, encompassing critical scientific presentations and targeted educational initiatives. Key components of Insmed’s ATS engagement included:
- Scientific Poster Sessions: Detailed presentations of data, including post-hoc analyses from the pivotal Phase III ASPEN trial, focused on Brinsupri’s impact on patient-reported respiratory symptoms and quality of life.
- Industry Theatre Session: A dedicated session provided a platform for pulmonologists to discuss real-world clinical experiences with Brinsupri and explore its application in NCFB management.
- Disease Burden Awareness: A poster presentation showcased survey results highlighting the significant impact of NCFB on patients and caregivers, underscoring the need for improved diagnostic and treatment pathways.
- On-Ground Presence: Insmed’s exhibition booth and surrounding areas were designed to raise disease awareness, provide in-depth information on Brinsupri, and share patient journeys, alongside details of the "InLighten" patient support program.
- ATS Initiative Support: Insmed’s financial backing of a landmark ATS initiative aimed at improving NCFB diagnosis through electronic health record analysis demonstrated a commitment to foundational advancements in the field.
- Educational Campaign Launch: The company unveiled the "Suspect Bronchiectasis (Suspect BE)" educational initiative to increase disease awareness among both healthcare professionals and the general public.
These concerted efforts reflect Insmed’s strategic vision to not only introduce a novel therapy but also to cultivate a comprehensive ecosystem of support and understanding for NCFB patients and clinicians.
Deep Dive into Brinsupri’s Efficacy Data
Central to Insmed’s ATS 2026 narrative was the presentation of compelling clinical data for Brinsupri. A significant scientific poster, unveiled on May 18th, presented a post-hoc analysis of patient-reported symptoms from the Phase III ASPEN trial (NCT04594369). This analysis focused on adult patients with NCFB and evaluated the efficacy of both 10mg and 25mg doses of brensocatib compared to placebo.
The findings revealed a clear trend of numerical improvements in respiratory symptoms across both treatment arms. Specifically, the mean observed overall Quality of Life-Bronchiectasis Respiratory Symptoms Score (QOL-B RSS) showed positive changes from baseline to week 52. For the 10mg dose, the QOL-B RSS improved from 59.8 to 67.9, while the 25mg dose saw an improvement from 61.9 to 70.3. In comparison, the placebo group experienced a more modest improvement from 60.0 to 66.3.
Further stratifying the data by on-study pulmonary exacerbation (PEx) status provided even more granular insights into Brinsupri’s therapeutic potential. The analysis categorized patients into three groups: no PEx, any PEx, or severe PEx (defined by requiring intravenous antibacterial treatment and/or hospitalization). Across these categories, both the 10mg and 25mg doses of brensocatib demonstrated symptom improvements relative to placebo. The most pronounced differences were observed in the 25mg group, suggesting a dose-dependent efficacy and highlighting the therapy’s ability to mitigate the impact of exacerbations on patient-reported outcomes. These findings are crucial as patient-reported outcomes are increasingly recognized as vital metrics in assessing treatment effectiveness, particularly in chronic conditions like NCFB.
Addressing the Burden of Bronchiectasis: Beyond Symptoms
Insmed’s commitment to understanding the broader impact of NCFB was evident in another poster presentation that detailed survey results examining the disease burden among patients and caregivers in the United States and Europe. The study, which involved 1,050 patients and 88 caregivers, shed light on the profound challenges faced by individuals living with NCFB.
A striking statistic revealed that 76.8% of patients (n=652) reported a decline in their health status following an exacerbation. This decline not only impacts physical health but also has significant repercussions on emotional well-being and social engagement. Perhaps more disturbingly, even among patients not currently experiencing exacerbations, a pervasive anxiety about the potential onset of future exacerbations was reported. This highlights the psychological toll of NCFB and the constant fear of symptom recurrence that can profoundly affect a patient’s quality of life.
The presentation of these survey results is strategically important, especially given the increasing focus by regulatory bodies on improving patient-reported outcomes and overall quality of life. By bringing this data to the forefront, Insmed advocates for enhanced patient care pathways and a more informed allocation of healthcare resources to address the multifaceted burden of NCFB.
Building Awareness and Driving Adoption
Beyond scientific data, Insmed dedicated significant resources to bolstering NCFB disease awareness and reinforcing Brinsupri’s clinical profile. The industry theatre session on May 19th served as a crucial forum for pulmonologists to share real-world clinical experiences with Brinsupri, fostering a collaborative environment for understanding the therapy’s practical application.
Insmed’s proactive engagement extends to foundational research and public health initiatives. In April 2026, the company provided research grant support to the ATS for a significant initiative aimed at improving the diagnosis of NCFB across the United States. This ambitious project will involve a comprehensive analysis of electronic health records from seven academic health systems over a 36-month period, with the primary goal of identifying patients who may have been misdiagnosed with bronchiectasis. Such efforts are vital for ensuring that patients receive timely and accurate diagnoses, enabling them to access appropriate treatment sooner.
Further bolstering awareness, Insmed launched the "Suspect Bronchiectasis (Suspect BE)" educational initiative in May 2026. This campaign is designed to educate both healthcare professionals and the public about the signs and symptoms of NCFB, encouraging individuals experiencing persistent respiratory issues, such as chronic cough, excessive mucus production, and recurrent lung infections, to seek prompt and proper medical evaluation.
Brinsupri’s Market Position and Future Outlook
Brinsupri’s journey has been marked by strategic regulatory approvals. Following its FDA approval in August 2025, the therapy subsequently received European and UK approvals in November 2025 and February 2026, respectively. These approvals position Brinsupri as the first non-antibiotic, anti-inflammatory treatment option specifically targeting NCFB. This represents a significant therapeutic shift away from the historical reliance on off-label antibiotic use, offering a more targeted and potentially safer approach to managing neutrophilic inflammation in the airways.
As the first-to-market DPP1 inhibitor in the respiratory field, Brinsupri is not merely an alternative but a potential paradigm shifter, poised to establish a new standard of care in bronchiectasis treatment.
Insmed’s financial performance and future projections underscore Brinsupri’s commercial momentum. During the company’s earnings call on May 7th, it was reported that Brinsupri’s global sales trajectory is on an upward trend, with net sales revenue reaching $207.9 million in Q1 2026. This performance reinforces the company’s full-year revenue guidance of at least $1 billion.
However, the global rollout has encountered a hurdle. Insmed has delayed the launch of Brinsupri in Europe, citing a lack of clarity surrounding the US government’s Most Favored Nation (MFN) drug pricing policy. This policy, which aims to link Medicare drug prices to lower prices paid in other developed countries, has introduced uncertainty into international pricing strategies. Updates on the European launch will be closely monitored, contingent on Insmed gaining greater clarity on pricing dynamics. Despite this delay, Brinsupri is still on track to achieve a first-to-market position in Europe, as no other late-stage NCFB pipeline assets are currently poised for imminent launch. When the European launch eventually materializes, it is anticipated to be well-received, bolstered by Brinsupri’s strong clinical profile, the extensive disease awareness groundwork laid by Insmed, and the growing prescriber confidence cultivated through initiatives like those showcased at ATS 2026.
The presence of Brinsupri at ATS 2026, coupled with its robust clinical data and strategic market positioning, signals a new era in the management of non-cystic fibrosis bronchiectasis. Insmed’s commitment to scientific advancement, disease awareness, and patient support suggests that Brinsupri is indeed on a trajectory to redefine treatment standards and improve the lives of countless individuals affected by this challenging condition.
Leave a Reply